Loading...
Docoh

Blonder Tongue Laboratories (BDRL)

Filed: 1 Jun 22, 5:05pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 1, 2022

 

Blonder Tongue Laboratories, Inc.

(Exact Name of registrant as specified in its charter)

 

Delaware 1-14120 52-1611421
(State or other jurisdiction
of incorporation)
 (Commission File Number) (I.R.S. Employer
Identification No.)

 

One Jake Brown Road, Old Bridge, New Jersey 08857

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (732) 679-4000

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, par value $.001 BDR NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously announced, the board of directors (the “Board”) of Blonder Tongue Laboratories, Inc. (the “Company”), based on the recommendation of the Compensation Committee of the Board, approved certain changes to the compensation to be received by directors. Those changes involved the issuance of options to purchase shares of the Company’s common stock to directors for their service on the Board and committees of the Board in lieu of the combination of cash payments and common stock grants that had comprised the compensation package for directors previously. The Board also indicated that it would reevaluate director compensation practices in advance of July 1, 2022. In connection with the reevaluation, the Board, based on the recommendation of the Compensation Committee of the Board, approved the grant of options to purchase 20,000 shares of the Company’s common stock to each of the directors. These grants are in lieu of any cash compensation that would otherwise be payable to directors during the remainder of 2022. The grant date is June 1, 2022, the options will vest on October 1, 2022 and have a term of 10 years from the grant date and an exercise price of $0.39, which is equal to the closing price of the Company’s common stock on NYSE American on June 1, 2022.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 BLONDER TONGUE LABORATORIES, INC.
  
 By:/s/ Eric Skolnik
  Eric Skolnik
  Senior Vice President and Chief Financial Officer

 

Date: June 1, 2022

 

 

2